Biomarin Pharmaceutical Inc (BMRN) Growth Rates Comparisons to Major Pharmaceutical Preparations Industry, Sector, Market. Sales, Income, EPS
CSIMarket Company Name, Ticker, Industry, else..
 
Biomarin Pharmaceutical Inc  (NASDAQ: BMRN)
 

Biomarin Pharmaceutical Inc Growth Comparisons

Select each growth Category to receive further Information




Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

BMRN Revenue Growth Rate Comparisons Company Industry Sector S&P 500
Y / Y Revenue Growth (Q2 MRQ) 19.91 % 12.24 % 9.19 % 10.9 %
Q / Q Revenue Growth (Q2 MRQ) 29.17 % -2.93 % -3.28 % 8.32 %
Y / Y Revenue Growth (for 12 months ending Q2 TTM) 11.2 % 9.25 % 7.98 % %
Sequential Revenue Growth (for 12 months ending Q2 TTM) 5.07 % 2.69 % 2.03 % 2.61 %
Revenue 5 Year Average Growth 11.6 % 7.41 % 8.65 % 10.59 %


BMRN's Growth Comparisons in II. Quarter 2026




Biomarin Pharmaceutical Inc improved it's Revenue by 19.91% year on year in the second quarter 2026, and outpaced the 12.24% rise in the Major Pharmaceutical Preparations industry, and 9.19% growth in the Healthcare sector. Comparing the second quarter sales growth, both Major Pharmaceutical Preparations industry and Biomarin Pharmaceutical Inc outperformed 10.9% overall market increase.

Company's sequential top-line increase was 29.17% from the first quarter. Average annual sales rise for Biomarin Pharmaceutical Inc is 11.6%, while S & P 500's average yearly sales growth is 10.59% over the five years, including only Businesses with the second quarter 2026 Results.

BMRN Growth Rates by Company's Segments

Segment Name
Y / Y
Sequential
Product
-
-
Royalty and Other
-
-
Reportable
-
-
VOXZOGO
113.38 %
114.85 %
VIMIZIM
87.8 %
92.47 %
NAGLAZYME
105.89 %
103.98 %
PALYNZIQ
112.13 %
150.93 %
Galafold
-
-
BRINEURA
102.24 %
109.06 %
ALDURAZYME
42.25 %
118.5 %
Pombiliti + Opfolda
-
-
KUVAN
78.75 %
102.36 %
ROCTAVIAN
55.98 %
444.35 %
Products Excluding Aldurazyme
-
-
Total
19.91 %
29.17 %


Growth Rates of BMRN's Income in the second quarter 2026


BMRN Operating Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Operating Income Change (Q2 MRQ) -59.94 % -8.69 % 5.13 % 97.6 %
Sequential Operating Income Change (Q2 MRQ) -14.44 % -4.52 % 0.89 % 48.13 %
Y / Y Operating Income Growth (Q2 TTM) -80.77 % 30.63 % 30.7 % 40.67 %
Sequential Operating Income Growth (Q2 TTM) -52.65 % -2.27 % 4.82 % 20.86 %
Operating Income 5 Year Avg. Change - 14.39 % 10.39 % 18.76 %


Income from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Income from Cont. Ops. Change (Q2 MRQ) -81.39 % -34.78 % -25.81 % 90.69 %
Sequential Income from Cont. Ops. Change (Q2 MRQ) -57.58 % -2.61 % -66.16 % 27.07 %
Y / Y Income from Cont. Ops. Change (Q2 TTM) -88.77 % 6.3 % 2.68 % 57.33 %
Sequential Income from Cont. Ops. Change (Q2 TTM) -72.85 % -10.02 % -5.02 % 18.65 %
Income from Cont. Ops. 5 Year Avg. Change -16.49 % -0.55 % 0.17 % -28.52 %

BMRN Net Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Net Income Growth (Q2 MRQ) -81.39 % -35.13 % -26.29 % 90.69 %
Q / Q Net Income Growth (Q2 MRQ) -57.58 % 2.8 % -0.86 % 27.07 %
Y / Y Net Income Change (Q2 TTM) -88.9 % 5.21 % 15.47 % 57.33 %
Sequential Net Income Change (Q2 TTM) -72.85 % -10.17 % -6.74 % 18.65 %
Net Income 5 Year Avg. Growth -16.49 % 14.55 % 9.21 % 22.96 %

BMRN's EPS Growth Rates


EPS from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS from Cont. Ops. Change (Q2 MRQ) -81.6 % -40.16 % -25.81 % 90.69 %
Sequential EPS from Cont. Ops. Change (Q2 MRQ) -58.18 % -7.73 % -66.16 % 27.07 %
Y / Y EPS from Cont. Ops. Change (Q2 TTM) -89.41 % - - -
Sequential EPS from Cont. Ops. Change (Q2 TTM) -73.91 % - - 4.88 %
EPS from Cont. Ops. 5 Year Avg. Growth -17.35 % -10.79 % 0.17 % -28.52 %



BMRN EPS Net Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS Net Growth (Q2 MRQ) -81.3 % -40.49 % -26.29 % -28.52 %
Q / Q EPS Net Growth (Q2 MRQ) -57.41 % -2.61 % -0.86 % 27.07 %
Y / Y EPS Net Change (for 12 months ending Q2 TTM) - - - 7.62 %
Sequential EPS Net Change (for 12 months ending Q2 TTM) -73.53 % - 0.15 % 4.93 %
EPS Net 5 Year Avg. Change - 14.55 % 9.21 % 22.96 %



As Biomarin Pharmaceutical Inc's income per share faded by -81.3% year on year in the second quarter, Major Pharmaceutical Preparations industry fell only by -40.49%, Biomarin Pharmaceutical Inc's second quarter performance was trailing Major Pharmaceutical Preparations, and underperformed the -26.29% EPS slide in the Healthcare sector. Weak second quarter income per share, in Major Pharmaceutical Preparations industry and within the Healthcare sector, were reflected in Biomarin Pharmaceutical Inc results which underperformed overall market.

Bottom-line fell by -57.41% from the first quarter results. Comparing the annual growth, income per share of 11.6% on average in last five years, to the S & P 500's, including only Businesses with the second quarter 2026 earnings, average yearly income per share growth is 22.96%. Biomarin Pharmaceutical Inc grew less than the market.

BMRN Cash Flow Growth Rates


Free Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Free Cash Flow Change (Q2 MRQ) -20.28 % 25.53 % 48.48 % 48.62 %
Sequential Free Cash Flow Change (Q2 MRQ) -32.98 % -42.35 % -46.96 % 34.18 %
Y / Y Free Cash Flow Change (Q2 TTM) 4.91 % 11.91 % 18.61 % 60.27 %
Sequential Free Cash Flow Change (Q2 TTM) -4.48 % 3.24 % 5.39 % 15.75 %
Free Cash Flow 5 Year Avg. Change - 1.86 % 0.92 % 8.28 %

Net Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Net Cash Flow Change (Q2 MRQ) - - - 339.02 %
Sequential Net Cash Flow Change (Q2 MRQ) - - - 216.68 %
Y / Y Net Cash Flow Change (Q2 TTM) 669.09 % - - 209.43 %
Sequential Net Cash Flow Change (Q2 TTM) - - - 152.64 %
Net Cash Flow 5 Year Avg. Change 11.74 % 29.88 % 6.46 % 1.06 %

Capital Expenditures Company Industry Sector S&P 500
Y / Y Capital Expenditures Change (Q2 MRQ) 97.21 % 11.25 % 8.23 % 120.03 %
Sequential Capital Expenditures Change (Q2 MRQ) 63.69 % -25.6 % -22.09 % 36.87 %
Y / Y Capital Expenditures Change (Q2 TTM) 74.6 % 16.65 % 7.86 % 109.38 %
Sequential Capital Expenditures Change (Q2 TTM) 14.66 % 2.92 % 1.6 % 23.05 %
Capital Expenditures 5 Year Avg. Change -4.2 % 8.94 % 9.18 % 14.72 %

Note
To view Detail Information & Trends click on Individual Category.
To see Industry, Sector or S&P 500 Performance, click on each Category respectivly, on the top of the Table.

For explanation of terms visit: Glossary
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Y/Y Annual




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.